Yüklüyor......
Tumor-derived interleukin-33 promotes tissue-resident CD8(+) T cells and is required for checkpoint blockade tumor immunotherapy
Immune checkpoint blockade (ICB) immunotherapy has revolutionized cancer treatment by prolonging overall survival of cancer patients. Despite advances in the clinical setting, the immune cellular network in the tumor microenvironment (TME) that mediates such therapy is not well understood. Interleuk...
Kaydedildi:
| Yayımlandı: | Cancer Immunol Res |
|---|---|
| Asıl Yazarlar: | , , , , , , , , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
2020
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7642190/ https://ncbi.nlm.nih.gov/pubmed/32917659 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2326-6066.CIR-19-1024 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|